AMA opposes BTC class
This article was originally published in The Tan Sheet
Executive Summary
The American Medical Association reaffirms its stance against a formal behind-the-counter drug class under consideration by FDA (see story, p. 5). A resolution introduced by AMA's Michigan delegation cites BTC prescribing as potentially "out of the realm of a pharmacist's training," which "might affect patient safety and quality of care." The AMA House of Delegates, which held its annual meeting June 15, did not pass the resolution because the association in 1984 adopted a policy opposing "a third transitional class of drugs." AMA questions FDA's authority to create a third drug class (1"The Tan Sheet" Nov. 19, 2007, p. 4)...
You may also be interested in...
BTC Proponents Cite Pharmacists’ Role; Opponents Question Need
There is one thing agreed on by opponents and proponents of assigning drugs to behind-the-counter status, including representatives from the pharmaceutical industry, drug retailers, the pharmacy and medical professions, researchers and consumer advocates: FDA will need a long time to reach a decision on the issue, they say
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.